PHATHOM PHARMACEUTICALS INC (PHAT)
US71722W1071 - Common Stock
We assign a fundamental rating of 2 out of 10 to PHAT. PHAT was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PHAT have multiple concerns. PHAT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year PHAT has reported negative net income.
PHAT had a negative operating cash flow in the past year.
PHAT had negative earnings in each of the past 5 years.
In the past 5 years PHAT always reported negative operating cash flow.
1.2 Ratios
PHAT has a worse Return On Assets (-87.70%) than 75.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.7% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-81.55%
ROA(5y)-77.52%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 83.54%, PHAT belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for PHAT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PHAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHAT has more shares outstanding
The number of shares outstanding for PHAT has been increased compared to 5 years ago.
Compared to 1 year ago, PHAT has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -5.19, we must say that PHAT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.19, PHAT is not doing good in the industry: 65.26% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.19 |
ROIC/WACCN/A
WACC8.69%
2.3 Liquidity
PHAT has a Current Ratio of 5.73. This indicates that PHAT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.73, PHAT is in the better half of the industry, outperforming 70.00% of the companies in the same industry.
A Quick Ratio of 5.68 indicates that PHAT has no problem at all paying its short term obligations.
PHAT's Quick ratio of 5.68 is fine compared to the rest of the industry. PHAT outperforms 71.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.73 | ||
| Quick Ratio | 5.68 |
3. Growth
3.1 Past
PHAT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.95%.
EPS 1Y (TTM)-48.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
PHAT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.14% yearly.
Based on estimates for the next years, PHAT will show a very strong growth in Revenue. The Revenue will grow by 351.06% on average per year.
EPS Next Y-46.9%
EPS Next 2Y-7.38%
EPS Next 3Y12.86%
EPS Next 5Y18.14%
Revenue Next Year12635.7%
Revenue Next 2Y1971.3%
Revenue Next 3Y880.19%
Revenue Next 5Y351.06%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
PHAT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHAT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PHAT's earnings are expected to grow with 12.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.38%
EPS Next 3Y12.86%
5. Dividend
5.1 Amount
No dividends for PHAT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PHATHOM PHARMACEUTICALS INC
NASDAQ:PHAT (12/24/2024, 7:31:33 PM)
After market: 7.5 0 (0%)7.5
-0.11 (-1.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners79.35%
Inst Owner Change25%
Ins Owners4.18%
Ins Owner Change-0.22%
Market Cap512.85M
Analysts84.29
Price Target25.79 (243.87%)
Short Float %27.49%
Short Ratio10.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.31%
Min EPS beat(2)-10.83%
Max EPS beat(2)13.44%
EPS beat(4)1
Avg EPS beat(4)-7.57%
Min EPS beat(4)-26.53%
Max EPS beat(4)13.44%
EPS beat(8)5
Avg EPS beat(8)4.54%
EPS beat(12)7
Avg EPS beat(12)1.05%
EPS beat(16)10
Avg EPS beat(16)-0.6%
Revenue beat(2)2
Avg Revenue beat(2)25.38%
Min Revenue beat(2)23.61%
Max Revenue beat(2)27.14%
Revenue beat(4)3
Avg Revenue beat(4)26.12%
Min Revenue beat(4)-8.43%
Max Revenue beat(4)62.16%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.03%
PT rev (3m)12.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.69%
EPS NY rev (1m)4.77%
EPS NY rev (3m)5.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.88%
Revenue NY rev (1m)13.32%
Revenue NY rev (3m)16.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 19.52 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.69
EYN/A
EPS(NY)-4.47
Fwd EYN/A
FCF(TTM)-3.62
FCFYN/A
OCF(TTM)-3.61
OCFYN/A
SpS0.38
BVpS-2.74
TBVpS-2.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.7% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.54% | ||
| FCFM | N/A |
ROA(3y)-81.55%
ROA(5y)-77.52%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 76.75% | ||
| Cap/Sales | 2.3% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.73 | ||
| Quick Ratio | 5.68 | ||
| Altman-Z | -5.19 |
F-Score3
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)171.79%
Cap/Depr(5y)428.08%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.68%
EPS Next Y-46.9%
EPS Next 2Y-7.38%
EPS Next 3Y12.86%
EPS Next 5Y18.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year12635.7%
Revenue Next 2Y1971.3%
Revenue Next 3Y880.19%
Revenue Next 5Y351.06%
EBIT growth 1Y-99.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.84%
EBIT Next 3Y15.92%
EBIT Next 5Y24.43%
FCF growth 1Y-67.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68%
OCF growth 3YN/A
OCF growth 5YN/A